Propofol protects human umbilical vein endothelial cells from cisplatin-induced injury

Vascular Pharmacology

Volumn 61, Issue 2-3, 2014, Pages 72-79

  Zhu, Minmin ^a,b   Chen, Jiawei ^a,b   Yin, Hua ^a,b   Jiang, Hui ^a,b   Wen, Meilin ^a,b   Miao, Changhong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cisplatin; Endothelium; ENOS; ICAM 1; Propofol

Indexed keywords

3 NITROTYROSINE; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CISPLATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; N(G) NITRO LEVO ARGININE METHYL ESTER HYDROCHLORIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROPOFOL; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; INTRAVENOUS ANESTHETIC AGENT; NOS3 PROTEIN, HUMAN;

ARTICLE; CELL ADHESION; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM INJURY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TOXICITY;

ANESTHETICS, INTRAVENOUS; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CISPLATIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MONOCYTES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROPOFOL; UP-REGULATION;

EID: 84900838604     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.04.001     Document Type: Article

References (62)

1. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin Nephrol 2003, 23:23460-23464.
2. Sekine I., Yamada K., Nokihara H., Yamamoto N., Kunitoh H., Ohe Y., et al. Bodyweight change during the first 5days of chemotherapy as an indicator of cisplatin renal toxicity. Cancer Sci 2007, 98:1408-1412.
3. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007, 334:115-124.
4. Dehne N., Lautermann J., Petrat F., Rauen U., de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 2001, 174:27-34.
5. van den Berg J.H., Beijnen J.H., Balm A.J., Schellens J.H. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006, 32:390-397.
6. Coradini P.P., Cigana L., Selistre S.G., Rosito L.S., Brunetto A.L. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007, 29:355-360.
7. Meijer C., de Vries E.G., Marmiroli P., Tredici G., Frattola L., Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999, 20:883-887.
8. Bianchi R., Brines M., Lauria G., Savino C., Gilardini A., Nicolini G., et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006, 12:2607-2612.
9. Tomaszewski A., Busselberg D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 2007, 28:49-58.
10. Bianchi R., Gilardini A., Rodriguez-Menendez V., Oggioni N., Canta A., Colombo T., et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 2007, 43:710-717.
11. de Vos F.Y., Willemse P.H., de Vries E.G., Gietema J.A. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 2004, 30:495-513.
12. Kohn S., Fradis M., Ben-David J., Zidan J., Robinson E. Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 2002, 26:371-382.
13. Kirchmair R., Walter D.H., Ii M., Rittig K., Tietz A.B., Murayama T., et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005, 111:2662-2670.
14. Kohn S., Fradis M., Podoshin L., Ben-David J., Zidan J., Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997, 21:289-299.
15. Luke D.R., Vadiei K., Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992, 7:1-7.
16. Winston J.A., Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985, 249:F490-F496.
17. Haugnes H.S., Wethal T., Aass N., Dahl O., Klepp O., Langberg C.W., et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010, 28:4649-4657.
18. Yu M., Han J., Cui P., Dai M., Li H., Zhang J., et al. Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway. Cancer Sci 2008, 99:391-397.
19. Katsuki S., Arnold W.P., Murad F. Effects of sodium nitroprusside, nitroglycerin, and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. J Cyclic Nucleotide Res 1977, 3:239-247.
20. Mellion B.T., Ignarro L.J., Ohlstein E.H., Pontecorvo E.G., Hyman A.L., Kadowitz P.J. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981, 57:946-955.
21. Ignarro L.J. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002, 53:503-514.
22. Ignarro L.J., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002, 90:21-28.
23. Toda N., Toda H. Coronary hemodynamic regulation by nitric oxide in experimental animals: recent advances. Eur J Pharmacol 2011, 667:41-49.
24. Cai S., Khoo J., Channon K.M. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res 2005, 65:823-831.
25. Chen X., Feng L., Jin H. Constant or fluctuating hyperglycemias increases cytomembrane stiffness of human umbilical vein endothelial cells in culture: roles of cytoskeletal rearrangement and nitric oxide synthesis. BMC Cell Biol 2013, 22:14:22.
26. Breithaupt-Faloppa A.C., Fantozzi E.T., Assis-Ramos M.M., Vitoretti L.B., Couto G.K., Rossoni L.V., et al. Protective effect of estradiol on acute lung inflammation induced by an intestinal ischemic insult is dependent on nitric oxide. Shock 2013, 40:203-209.
27. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68.
28. Cartwright J.E., Whitley G.S., Johnstone A.P. Endothelial cell adhesion molecule expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide. Exp Cell Res 1997, 235:431-434.
29. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
30. Sekijima T., Tanabe A., Maruoka R., Fujishiro N., Yu S., Fujiwara S., et al. Impact of platinum-based chemotherapy on the progression of atherosclerosis. Climacteric 2011, 14:31-40.
31. Lee Y.J., Kang D.G., Kim J.S., Lee H.S. Lycopus lucidus inhibits high glucose-induced vascular inflammation in human umbilical vein endothelial cells. Vascul Pharmacol 2008, 48:38-46.
32. Zhu M., Chen J., Tan Z., Wang J. Propofol protects against high glucose-induced endothelial dysfunction in human umbilical vein endothelial cells. Anesth Analg 2012, 114:303-309.
33. Zhu M., Chen J., Jiang H., Miao C. Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells. Cardiovasc Diabetol 2013, 11:12:13.
34. Mathy-Hartert M., Deby-Dupont G., Hans P., Deby C., Lamy M. Protective activity of propofol, Diprivan and intralipid against active oxygen species. Mediators Inflamm 1998, 7:327-333.
35. Vogelzang N.J., Frenning D.H., Kennedy B.J. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980, 64:1159-1160.
36. Doll D.C., List A.F., Greco F.A., Hainsworth J.D., Hande K.R., Johnson D.H. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986, 105:48-51.
37. Lederman G.S., Garnick M.B. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol 1987, 137:1236-1237.
38. Grumbach I.M., Chen W., Mertens S.A., Harrison D.G. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005, 39:595-603.
39. Rodriguez-Crespo I., Gerber N.C., Ortiz de Montellano P.R. Endothelial nitric-oxide synthase expression in Escherichia coli, spectroscopic characterization, and role of tetrahydrobiopterin in dimer formation. J Biol Chem 1996, 271:11462-11467.
40. Michell B.J., Chen Z.P., Tiganis T., Stapleton D., Katsis F., Power D.A., et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001, 276:17625-17628.
41. Xia Y., Tsai A.L., Berka V., Zweier J.L. Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998, 273:25804-25808.
42. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S.S., Karoui H., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95:9220-9225.
43. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844.
44. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
45. Stuehr D.J., Griffith O.W. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 1992, 65:287-346.
46. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999, 43:274-278.
47. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
48. Kim C.S., Choi J.S., Park J.W., Bae E.H., Ma S.K., Lee J., et al. Altered regulation of nitric oxide and natriuretic peptide system in cisplatin-induced nephropathy. Regul Pept 2012, 174:65-70.
49. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999, 443:285-289.
50. Michell B.J., Griffiths J.E., Mitchelhill K.I., Rodriguez-Crespo I., Tiganis T., Bozinovski S., et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999, 9:845-848.
51. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
52. Rask-Madsen C., King G.L. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005, 25:487-496.
53. West M.B., Ramana K.V., Kaiserova K., Srivastava S.K., Bhatnagar A. L-Arginine prevents metabolic effects of high glucose in diabetic mice. FEBS Lett 2008, 582:2609-2614.
54. Kim H.J., Lee J.H., Kim S.J., Oh G.S., Moon H.D., Kwon K.B., et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010, 30:3933-3946.
55. Khan R., Khan A.Q., Qamar W., Lateef A., Ali F., Rehman M.U., et al. Chrysin abrogates cisplatin-induced oxidative stress, p53 expression, goblet cell disintegration and apoptotic responses in the jejunum of Wistar rats. Br J Nutr 2012, 108:1574-1585.
56. Mukhopadhyay P., Horváth B., Zsengellér Z., Zielonka J., Tanchian G., Holovac E., et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med 2012, 52:497-506.
57. Kahraman S., Demiryurek A.T. Propofol is a peroxynitrite scavenger. Anesth Analg 1997, 84:1127-1129.
58. Thiry J.C., Hans P., Deby-Dupont G., Mouythis-Mickalad A., Bonhomme V., Lamy M. Propofol scavenges reactive oxygen species and inhibits the protein nitration induced by activated polymorphonuclear neutrophils. Eur J Pharmacol 2004, 499:29-33.
59. Wang L., Wu B., Sun Y., Xu T., Zhang X., Zhou M., et al. Translocation of protein kinase C isoforms is involved in propofol-induced endothelial nitric oxide synthase activation. Br J Anaesth 2010, 104:606-612.
60. Aarts L., van der Hee R., Dekker I., de Jong J., Langemeijer H., Bast A. The widely used anesthetic agent propofol can replace alpha-tocopherol as an antioxidant. FEBS Lett 1995, 357:83-85.
61. Heller R., Werner-Felmayer G., Werner E.R. Alpha-Tocopherol and endothelial nitric oxide synthesis. Ann N Y Acad Sci 2004, 1031:74-85.
62. Desideri G., Marinucci M.C., Tomassoni G., Masci P.G., Santucci A., Ferri C. Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients. J Clin Endocrinol Metab 2002, 87:2940-2945.